NCT04840914

A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

A Single-Dose Study Evaluating Different Dose Levels and Subcutaneous Infusion Durations on Safety, Pharmacokinetics, and Pharmacodynamics of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits.

Conditions

• Chronic Heart Failure With Reduced Ejection Fraction

Interventions

Type	Name	Description
DRUG	LY3461767	Administered SC.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2021-06-01
• Primary completion: 2024-05-09
• Completion: 2024-05-09
• First posted: 2021-04-12
• Last updated: 2024-05-30

Locations

7 sites across 2 countries: United States, Japan

Regulatory

• FDA-regulated drug study